Abstract
Patients with ovarian cancer relapsing during first-line treatment (refractory) or in the following few months (platinum-resistant) are a very heterogeneous group with various biological tumor behaviors. As this condition is linked to an unfavorable prognosis, the main objective of treatment is to palliate symptoms and preserve quality of life. While traditional chemotherapy may help to achieve this, new biological agents that have been introduced or are under development are expected to improve the quality of life and outcomes for patients with advanced ovarian cancer. This case report describes the clinical history of a 67-year-old woman with bilateral ovarian high grade serous papillary adenocarcinoma with lymph node and omentum metastasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
